Key Points:
1.	Duloxetine demonstrated greater efficacy in improving motor and non-motor symptoms, overall clinical status, and cognitive function compared to traditional treatments in patients with comorbid depression in Parkinson's Disease.
2.	Patients treated with duloxetine exhibited statistically significant improvements in motor function, cognitive function, and overall clinical status, highlighting its potential comprehensive benefits in managing comorbid depression in Parkinson's Disease.
3.	The incidence of adverse events was similar between the duloxetine group and the traditional treatment group, indicating comparable tolerability of both approaches.